natgillin/translations-raw huggingface dataset:
− 31.25x109 bacteria* of each of the following V. cholerae O1 strains: Inaba classical biotype (heat inactivated), Inaba El Tor biotype (formalin inactivated), Ogawa classical biotype (heat inactivated), Ogawa classical biotype (formalin inactivated).
− 31,25 x 109 bakterij* vsake od naslednjih sevov bakterije V. cholerae O1: klasični biotip Inaba
Children less than 2 years
Odrasli in otroci >6 let
31.25x109 bacteria* of each of the following V. cholerae O1 strains: Inaba classical biotype (heat inactivated), Inaba El Tor biotype (formalin inactivated), Ogawa classical biotype (heat inactivated), Ogawa classical biotype (formalin inactivated).
(inaktiviran s toploto), biotip Inaba El Tor (inaktiviran s formalinom), klasični biotip Ogawa (inaktiviran s toploto), klasični biotip Ogawa (inaktiviran s formalinom).
• Difficulty in sleeping
• otekanje bezgavk,
Avoid food and drink starting 1 hour before until 1 hour after the vaccination.
Eno uro pred cepljenjem do ene ure po njem ne uživajte hrane in pijače.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS DUKORAL, vial label 1 dose
OVOJNINAH DUKORAL, nalepka za vialo - 1 odmerek
Respiratory symptoms (including rhinitis and cough) Gastrointestinal disorders Uncommon Diarrhoea, abdominal cramps, abdominal pain, stomach/abdominal gurgling (gas), abdominal discomfort
Bolezni dihal, prsnega koša in mediastinalnega prostora Redki dihalni simptomi (vključno z rinitisom in kašljem)
The usual dose of Zepatier is one tablet taken once a day for 12 weeks.
Običajni odmerek zdravila Zepatier je ena tableta enkrat dnevno v obdobju 12 tednov.
The full EPAR for Zepatier can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zepatier je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What measures are being taken to ensure the safe and effective use of Zepatier?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Zepatier?
The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Zepatier's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zato zaključil, da so koristi zdravila Zepatier večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Other information about Zepatier
Druge informacije o zdravilu Zepatier
This is a summary of the European public assessment report (EPAR) for Zepatier.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Zepatier.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zepatier have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo zdravstveni delavci in bolniki upoštevati za varno in učinkovito uporabo zdravila Zepatier, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Elbasvir blocks the action of a protein called ‘NS5A', while grazoprevir blocks an enzyme called ‘NS3/4A protease'.
Elbasvir zavira delovanje beljakovine, imenovane „NS5A“, medtem ko grazoprevir zavira delovanje encima, imenovanega „proteaza NS3/4A“.
The available data in patients with genotype 3 virus were not sufficient to support the use of Zepatier for this genotype.
Razpoložljivi podatki pri bolnikih z virusom genotipa 3 niso bili zadostni, da bi podprli uporabo zdravila Zepatier pri tem genotipu.
The most common side effects with Zepatier (which may affect more than 1 in 10 people) are tiredness and headache.
Najpogostejša neželena učinka zdravila Zepatier (ki lahko prizadeneta več kot 1 osebo od 10) sta utrujenost in glavobol.
In some cases, treatment may be longer and Zepatier may be used together with another medicine called ribavirin.
V nekaterih primerih je zdravljenje lahko daljše, zdravilo Zepatier pa se lahko uporablja skupaj z drugim zdravilom, ribavirinom.
This was considered acceptable because chronic hepatitis C virus is very rarely cured without treatment and, at the time the studies started, other antiviral medications such as Zepatier were not available.
To je bilo sprejemljivo, ker se kronični virus hepatitisa C zelo redko ozdravi brez zdravljenja in ker v času začetka študij druga protivirusna zdravila, kot je zdravilo Zepatier, še niso bila na voljo.
Zepatier is available as tablets which contain 50 mg elbasvir and 100 mg grazoprevir.
Zdravilo Zepatier je na voljo v obliki tablet, ki vsebujejo 50 mg elbasvirja in 100 mg grazoprevirja.
In most of the studies, treatment with Zepatier was not compared with another treatment or no treatment.
V večini študij zdravljenja z zdravilom Zepatier niso primerjali z drugim zdravilom ali odsotnostjo zdravljenja.
Zepatier was well tolerated with a favourable safety profile.
Zdravilo Zepatier so bolniki dobro prenašali in ima ugoden varnostni profil.
What are the risks associated with Zepatier?
Kakšna tveganja so povezana z zdravilom Zepatier?
What is Zepatier and what is it used for?
Kaj je zdravilo Zepatier in za kaj se uporablja?
What benefits of Zepatier have been shown in studies?
Kakšne koristi je zdravilo Zepatier izkazalo v študijah?
It is not intended to provide practical advice on how to use Zepatier.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Why is Zepatier approved?
Zakaj je bilo zdravilo Zepatier odobreno?
Benefit was also seen in patients also infected with HIV or who had chronic (long-term) kidney disease.
Koristne učinke so opazili tudi pri bolnikih, okuženih z virusom HIV, in bolnikih s kronično (dolgotrajno) ledvično boleznijo.
Zepatier with or without ribavirin has been investigated in eight main studies involving around 2,000 patients infected with hepatitis C virus of various genotypes whose liver was working normally or adequately.
Zdravilo Zepatier z ribavirinom ali brez njega so preučevali v osmih glavnih študijah, ki so vključevale okrog 2 000 bolnikov, okuženih z virusom hepatitisa C različnih genotipov, pri katerih so jetra delovala normalno ali ustrezno.
For more information about treatment with Zepatier, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Zepatier preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
For practical information about using Zepatier, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Zepatier naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Zepatier must not be used in patients with moderately or severely reduced liver function (Child-Pugh class B or C cirrhosis).
Zdravilo Zepatier se ne sme uporabljati pri bolnikih z zmerno ali močno zmanjšanim delovanjem jeter (cirozo razreda B ali C po Child-Pughu).
Zepatier can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in the management of patients with chronic hepatitis C.
Izdaja zdravila je le na recept, zdravljenje pa mora uvesti in spremljati zdravnik z izkušnjami pri zdravljenju bolnikov s kroničnim hepatitisom C.
By blocking these proteins, Zepatier stops the hepatitis C virus from multiplying and infecting new cells.
Zdravilo Zepatier z zaviranjem teh beljakovin prepreči virusu hepatitisa C, da bi se razmnoževal in okužil nove celice.
Zepatier is an antiviral medicine used to treat adults with chronic (long-term) hepatitis C, an infectious disease that affects the liver, caused by the hepatitis C virus.
Zdravilo Zepatier je protivirusno zdravilo, namenjeno zdravljenju odraslih s kroničnim (dolgotrajnim) hepatitisom C (nalezljivo boleznijo, ki prizadene jetra in jo povzroča virus hepatitisa C).
Zepatier has been shown to be highly effective in clearing the hepatitis C virus genotypes 1a, 1b and 4 from the blood of patients with or without compensated cirrhosis, including patients also infected with HIV or who have chronic kidney disease.
Zdravilo Zepatier se je izkazalo za zelo učinkovito pri odstranjevanju virusa hepatitisa C genotipov 1a, 1b in 4 iz krvi bolnikov s kompenzirano cirozo ali brez nje, vključno z bolniki, hkrati okuženimi z virusom HIV, ali bolniki s kronično ledvično boleznijo.
For the full list of all side effects reported with Zepatier, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Zepatier, glejte navodilo za uporabo.
For patients with genotype 4 virus, 94% of patients (61 out of 65 patients) treated with Zepatier tested negative compared with 100% (8 out of 8 patients) treated with Zepatier and ribavirin.
Pri bolnikih z virusom genotipa 4 so bili testi za virus negativni pri 94 % bolnikov (61 bolnikih od 65), ki so se zdravili z zdravilom Zepatier, v primerjavi s 100 % bolnikov (8 bolnikov od 8), ki so se zdravili z zdravilom Zepatier in ribavirinom.
It must not be used together with medicines such as the antibiotic rifampicin, certain HIV medicines and ciclosporin (used to prevent organ rejection) since Zepatier may affect the way these medicine work.
Zdravilo Zepatier se ne sme jemati skupaj z zdravili, kot so antibiotik rifampicin, določena zdravila za zdravljenje HIV in ciklosporin (ki se uporablja za preprečevanje zavrnitve organov), ker lahko vpliva na način delovanja teh zdravil.
For patients with genotype 1a virus, 93% of patients (483 out of 519 patients) treated with Zepatier tested negative compared with 95% (55 out of 58 patients) on Zepatier with ribavirin.
Pri bolnikih z virusom genotipa 1a so bili testi za virus negativni pri 93 % bolnikov (483 bolnikih od 519), ki so se zdravili z zdravilom Zepatier, v primerjavi s 95 % bolnikov (55 bolnikih od 58), ki so se zdravili z zdravilom Zepatier in ribavirinom.
It must also not be used with the herbal remedy St. John's wort (used for depression and anxiety), or the epilepsy medicines carbamazepine and phenytoin because these medicines may affect the way Zepatier works.
Prav tako se ne sme uporabljati skupaj s šentjanževko, zdravilom rastlinskega izvora (ki se uporablja pri depresiji in tesnobnosti), ali s karbamazepinom in fenitoinom, zdraviloma za zdravljenje epilepsije, ker lahko ta zdravila vplivajo na način delovanja zdravila Zepatier.
The active substances in Zepatier, elbasvir and grazoprevir, block two proteins essential for the hepatitis C virus to multiply.
Zdravilni učinkovini v zdravilu Zepatier, elbasvir in grazoprevir, zavirata beljakovini, ki ju virus hepatitisa C potrebuje za razmnoževanje.
Zepatier contains the active substances elbasvir and grazoprevir.
Zdravilo Zepatier vsebuje zdravilni učinkovini elbasvir in grazoprevir.
How does Zepatier work?
Kako zdravilo Zepatier deluje?
How is Zepatier used?
Kako se zdravilo Zepatier uporablja?
In all studies, the main measure of effectiveness was the number of patients whose blood tests did not show any sign of hepatitis C virus 12 weeks after the end of treatment.
Glavno merilo učinkovitosti v vseh študijah je bilo število bolnikov, pri katerih krvne preiskave 12 tednov po koncu zdravljenja niso pokazale prisotnosti virusa hepatitisa C. Skupna analiza rezultatov študij je pokazala, da so bili pri 96 % bolnikov z virusom genotipa 1b (301 bolnik od 312) testi za virus po koncu 12-tedenskega zdravljenja z zdravilom Zepatier negativni.
Zepatier is recommended for use in patients infected with hepatitis C virus genotypes 1a, 1b and 4 who may or may not have compensated liver cirrhosis (scarring of the liver but the liver is still able to work adequately).
Obstaja več različic (genotipov) virusa hepatitisa C. Zdravilo Zepatier se priporoča za uporabo pri bolnikih, okuženih z virusom hepatitisa C genotipa 1a, 1b ali 4, ki imajo kompenzirano jetrno cirozo (brazgotinjenje jeter, pri čemer jetra še vedno ustrezno delujejo) ali ne.
The study looked at
V študiji so
The company also provided data from 2 studies in a total of 150 healthy participants.
Podjetje je prav tako predložilo podatke iz dveh študij, v katerih je sodelovalo 150 zdravih preskušancev.
It was to be available as a solution for injection into a muscle.
Na voljo naj bi bilo v obliki raztopine za injiciranje v mišico.
Exposure to high amounts of radiation can result in multiple organ failure and death.
Izpostavljenost velikim količinam sevanja lahko povzroči odpoved več organov in smrt.
These studies examined the medicine's effects on humans and how the medicine was broken down and removed from the body.
V teh dveh študijah so proučevali učinke zdravila na ljudi ter način njegove razgradnje in izločanja iz telesa.
In addition, there were questions about whether the company had sufficient measures in place to ensure the manufacturing of Entolimod TMC was properly controlled.
Poleg tega se je pojavilo vprašanje, ali je imelo podjetje vzpostavljene zadostne ukrepe za zagotovitev pravilnega nadzora nad proizvodnjo zdravila Entolimod TMC.
Because dangerous doses of radiation cannot be given to humans, the effects of Entolimod TMC against radiation were evaluated in a main study involving 179 macaque monkeys.
Ker ljudje ne smejo prejeti nevarnih odmerkov sevanja, so učinke zdravila Entolimod TMC za preprečevanje sevanja ocenili v glavni študiji, v kateri je sodelovalo 179 opic makakov.
Withdrawal of the marketing authorisation application for Entolimod TMC (entolimod) EMA/632431/2018
Umik vloge za pridobitev dovoljenja za promet z zdravilom Entolimod TMC (entolimod) EMA/632431/2018
Entolimod TMC is a medicine that contains the active substance entolimod.
Entolimod TMC je zdravilo, ki vsebuje učinkovino entolimod.
The CHMP's main concern was that there was insufficient evidence from studies, including the macaque study, to determine the effects of the medicine in humans and how it should be used.
Njegov glavni zadržek je bil, da ni dovolj dokazov iz študij, vključno s študijo z makaki, da bi lahko ugotovili učinke zdravila pri ljudeh in način njegove uporabe.
how many of them survived high doses of radiation when given different doses of Entolimod TMC or placebo (a dummy treatment).
ugotavljali, koliko med njimi je preživelo velike odmerke sevanja, ko so prejeli različne odmerke zdravila Entolimod TMC ali placebo (zdravilo brez učinkovine).
In its letter notifying the Agency of the withdrawal of the application, the company stated that they needed more time to generate the additional data required to address some of the points raised by the CHMP.
Podjetje je v dopisu, s katerim je agencijo obvestilo o umiku vloge, navedlo, da potrebuje več časa za pridobitev dodatnih podatkov za odgovore na vprašanja, ki jih je zastavil odbor CHMP.
The company informed the CHMP that there are no ongoing clinical trials or compassionate use programmes with the medicine.
Podjetje je odbor CHMP obvestilo, da trenutno ne potekajo klinična preskušanja ali programi sočutne uporabe zdravila.
Entolimod TMC was expected to be used to reduce the risk of death in adults and children from 2 years of age exposed to a high amount of radiation following a disaster such as a nuclear accident.
Zdravilo Entolimod TMC naj bi se uporabljalo za zmanjševanje tveganja smrti pri odraslih in otrocih, starejših od dveh let, ki so izpostavljeni visokim količinam sevanja po nesrečah, kot je jedrska nesreča.
Entolimod TMC was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 11 January 2016, for the treatment of acute radiation syndrome.
Zdravilo Entolimod TMC je bilo 11. januarja 2016 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni) za zdravljenje akutnega radiacijskega sindroma.
Entolimod TMC works by attaching to a protein on the surface of cells known as toll-like receptor 5 (TLR5).
Zdravilo Entolimod TMC deluje z vezanjem na beljakovino na površini celic, znano kot tollu-podoben receptor 5 (TLR5).
Withdrawal of the marketing authorisation application for Entolimod TMC (entolimod)
Umik vloge za pridobitev dovoljenja za promet z zdravilom Entolimod TMC (entolimod)
The attachment to TLR5 triggers production of substances whose effects are expected to reduce damage to the body caused by radiation.
Z vezanjem na beljakovino TLR5 pride do nastanka snovi, katerih učinki naj bi zmanjšali okvare na telesu, ki jih je povzročilo sevanje.
On 31 July 2018, TMC Pharma Services Ltd officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wished to withdraw its application for a marketing authorisation for Entolimod TMC, intended to be used to reduce the risk of death following exposure to potentially lethal amounts of radiation.
Podjetje TMC Pharma Srvices Ltd je 31. julija 2018 uradno obvestilo Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za pridobitev dovoljenja za promet z zdravilom Entolimod TMC, namenjenim zmanjševanju tveganja za smrt po izpostavljenosti morebitno smrtnim količinam sevanja.
Therefore, at the time of the withdrawal, the CHMP was of the opinion that the benefits of Entolimod TMC did not outweigh its risks.
Zato je odbor CHMP ob umiku vloge menil, da koristi zdravila Entolimod TMC ne odtehtajo z njim povezanih tveganj.
Based on the review of the data, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Entolimod TMC could not have been approved to reduce the risk of death following exposure to potentially lethal amounts of radiation.
Odbor CHMP je na podlagi pregleda podatkov ob umiku vloge izrazil določene zadržke in je začasno menil, da zdravila Entolimod TMC ni mogoče odobriti za zmanjševanje tveganja smrti po izpostavljenosti morebitnim smrtnim količinam sevanja.
How does Entolimod TMC work?
Kako zdravilo Entolimod TMC deluje?
What is Entolimod TMC?
Kaj je zdravilo Entolimod TMC?
What was Entolimod TMC expected to be used for?
Za kaj naj bi se zdravilo Entolimod TMC uporabljalo?
Invented name Strength Pharmaceutical form Route of administration Packaging
Številka EU zaščiteno ime jakost farmacevtska oblika pot uporabe ovojnina velikost pakiranja
Thereafter, steady concentrations are maintained for up to 96 hours.
Nato se stalna koncentracija vzdržuje do 96 ur.
Change the patch on the same two days every week, for example, every Sunday and Wednesday or Monday and Thursday.
Obliž vedno menjajte na enaka dneva v tednu, na primer vsako nedeljo in sredo, ali vsak ponedeljek in četrtek.
Date of first authorisation: 15/06/2004 Date of latest renewal: 30/04/2009
Datum prve odobritve: 15/06/2004 Datum zadnjega podaljšanja: 30/04/2009
The pump is now primed and ready for use.
Črpalka je zdaj napolnjena in pripravljena za uporabo.
The metered dose should be applied immediately.
Odmerjeni odmerek je treba uporabiti takoj.
Press for at least 10 seconds to make sure the patch will stay in place.
Pritiskajte vsaj 10 sekund in se prepričajte, da bo ostal na svojem mestu.
Of these 188 patients (38%) were 65 years of age and older and exhibited no overall differences in safety or effectiveness compared to younger patients.
Med temi je bilo 188 bolnikov (38 %) starih 65 let in več; pri teh se v primerjavi z mlajšimi bolniki ni pokazala splošna razlika v varnosti ali učinkovitosti.
Approximately 75% of patients had no prior pharmacological treatment for incontinence.
Približno 75 % bolnikov se predhodno ni farmakološko zdravilo zaradi inkontinence.
Bathing, showering, swimming and exercise:
Kopanje, prhanje, plavanje in telovadba:
Social relationships subscale -15.2 (20.07)
Podlestvica družbena razmerja -15,2 (20,07)
If it does, try putting the same patch back on the same spot.
Če se to zgodi, ga skušajte ponovno nalepiti na isto mesto.
If you forget to change the patch after 3-4 days:
Če po 3-4 dneh pozabite zamenjati obliž:
The results of the study indicate that showering after one hour does not affect the overall systemic exposure to oxybutynin.
Rezultati študije so pokazali, da prhanje po eni uri ne vpliva na splošno sistemsko izpostavljenost oksibutininu.
Allow the area to dry completely.
Počakajte, da se mesto popolnoma posuši.
The most commonly reported adverse drug reactions were application site reactions, occurring in 23.1% of patients.
Najpogostejši neželeni učinki na zdravilo so bile reakcije na mestu uporabe, ki so se pojavile pri 23,1 % bolnikov.
- Freshly washed, but dry and cool (wait a few minutes after taking a hot bath or shower).
- Pravkar umito, vendar suho in hladno (počakajte nekaj minut, če ste se prhali ali kopali v vroči vodi).
These results were evident after the first month of treatment and were maintained throughout double-blind treatment as shown in the table below.
Ti rezultati so bili opazni po prvem mesecu zdravljenja, ohranili pa so se ves čas dvojno slepega zdravljenja, kot je prikazano v preglednici spodaj.
Patients should be monitored until symptoms resolve.
Bolnike je treba spremljati, dokler simptomi ne izginejo.
Both patients recovered fully with symptomatic treatment.
Oba bolnika sta po simptomatskem zdravljenju popolnoma okrevala.
The majority of patients were Caucasian (86.3%) and female (89.2%), with a mean age of 59.4 years (range: 18 to 88 years).
Večina bolnikov je bila belcev (86,3 %) in žensk (89,2 %), povprečna starost pa je bila 59,4 leta (razpon: od 18 do 88 let).
After the sachets are opened and contents expelled, the gel should be used immediately.
Ko so vrečice odprte in vsebina iztisnjena, je treba gel uporabiti takoj.
How to use the sachets:
Kako uporabljati vrečice:
If a patient experiences such events, drug discontinuation should be considered.
Če se pri bolniku pojavijo takšni dogodki, je treba razmisliti o prekinitvi zdravljenja.
To apply Kentera: Step 1: Choose a spot for the patch that is:
Namestitev obliža Kentera: 1. korak: Izberite mesto za namestitev obliža, ki je:
Apply as directed above.
Nanesite skladno z navodili zgoraj.
If not, take it off and put a new patch on a new spot.
Če ne, ga snemite in na novo mesto nanesite nov obliž.
No matter what day this happens, continue with the same twice-a-week schedule for your next patch, even if it means changing the new patch before 3 to 4 days have elapsed.
Ne glede na to, kateri dan se to zgodi, se držite svojega urnika nanosa dvakrat tedensko za naslednji obliž, četudi to pomeni, da ga boste morali zamenjati, preden pretečejo 3 ali 4 dnevi.
The MAH must ensure that the system of pharmacovigilance, presented in Module 1.8.1 of the Marketing Authorisation, is in place and functioning before and whilst the product is on the market.
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, kot je predložen v modulu 1.8.1. dovoljenja za promet z zdravilom, vzpostavljen in deluje, preden da zdravilo v promet in ves čas trženja zdravila.
Apply immediately upon opening.
Uporabite takoj po odprtju.
Apply a Kentera patch as soon as you realise your patch is missing, or you have missed a scheduled day of application.
Obliž Kentera namestite takoj, ko ugotovite, da manjka, ali če ste zamudili načrtovani dan uporabe.
Steady-state conditions are reached after the seventh day of administration.
Stanje dinamičnega ravnovesja se doseže po sedmem dnevu uporabe.
Northern Ireland BT51 3RP
Severna Irska BT51 3RP
Do not expose the patch to the sun.
Obliža ne izpostavljajte soncu.
The product should not come in contact with an open flame.
Zdravilo ne sme priti v stik z odprtim ognjem.
Repeat until the sachet is empty.
Ponavljajte, dokler vrečice ne izpraznite.
If it sticks firmly all over, leave it on.
Če je povsod dobro prilepljen, ga pustite na koži.
WHAT KENTERA IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO KENTERA IN ZA KAJ GA UPORABLJAMO
For transdermal use only.
Samo za transdermalno uporabo.
Important: Kentera is for application to the skin only.
Pomembno: Zdravilo Kentera se nanaša samo na kožo.
- If you are hypersensitive (allergic) to oxybutynin or any of the ingredients of Kentera.
- Če ste preobčutljivi (alergični) na oksibutinin ali druge sestavine zdravila Kentera.
You should wear each patch all the time until you apply a new one.
Obliž nosite ves čas, vse dokler ne nanesete novega.